The immunogenicity of pneumococcal polysaccharides in infants and children: A meta-regression

Vaccine

Volumn 29, Issue 40, 2011, Pages 6838-6847

  Laferriere, Craig ^a  

^a Canvax   (Canada)

Author keywords

Immunogenicity; Infants; Meta regression; Pneumococcus; Polysaccharide; Serotype; T independent

Indexed keywords

ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GROSS NATIONAL PRODUCT; HUMAN; IMMUNIZATION; IMMUNOGENICITY; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SAMPLING; SEROTYPE; SYSTEMATIC REVIEW;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CHILD, PRESCHOOL; HUMANS; INFANT; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; REGRESSION ANALYSIS; STREPTOCOCCUS PNEUMONIAE;

EID: 80052307263     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.097     Document Type: Review

References (73)

1. Kamerling J.P. Pneumococcal polysccharides: a chemical view. Streptococus pneumoniae, molecular biology and mechanisms of disease 2000, 81-114. Mary Ann Liebert Inc., Larchmont, NY. A. Tomasz (Ed.).
2. Balmer P., Borrow R., Arkwright P.D. The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype Ab protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine. Vaccine 2007, 25(34):6321-6325.
3. Balloch A., Licciardi P.V., Russell F.M., Mulholland E.K., Tang M.L. Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine. J Allergy Clin Immunol 2010, 126(August (2)):395-397.
4. Barrett D.J., Lee C.G., Ammann A.J., Ayoub E.M. IgG and IgM pneumococcal polysaccharide Ab responses in infants. Pediatr Res 1984, 18(11):1067-1071.
5. Blum M.D., Dagan R., Mendelman P.M., Pinsk V., Giordani M., Li S., et al. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine 2000, 18(22):2359-2367.
6. Borgoño J.M., McLean A.A., Vella P.P., Woodhour A.F., Canepa I., Davidson W.L., et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med 1978, 157(1):148-154.
7. Cowan M.J., Ammann A.J., Wara D.W., Howie V.M., Schultz L., Doyle N., et al. Pneumococcal polysaccharide immunization in infants and children. Pediatrics 1978, 62(5):721-727.
8. Douglas R.M., Paton J.C., Duncan S.J., Hansman D.J. Ab response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983, 148(1):131-137.
9. Karma P., Luotonen J., Timonen M., Pöntynen S., Pukander J., Herva E., et al. Efficacy of pneumococcal vaccination against recurrent Otitis media. Preliminary results of a field trial in Finland. Ann Otol Rhinol Laryngol Suppl 1980, 89(3 Pt 2):357-362.
10. Koskela M., Leinonen M. Comparison of ELISA and RIA for measurement of pneumococcal antibodies before and after vaccination with 14-valent pneumococcal capsular polysaccharide vaccine. J Clin Pathol 1981, 34(1):93-98.
11. Koskela M., Leinonen M., Häivä V.M., Timonen M., Mäkelä P.H. First and second dose Ab responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis 1986, 5(1):45-50.
12. Lawrence E.M., Edwards K.M., Schiffman G., Thompson J.M., Vaughn W.K., Wright P.F. Pneumococcal vaccine in normal children. Primary and secondary vaccination. Am J Dis Child 1983, 137(9):846-850.
13. Leach A.J., Morris P.S., Mackenzie G., McDonnell J., Balloch A., Carapetis J., et al. Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population. Vaccine 2008, 26(31):3885-3891.
14. Leinonen M., Säkkinen A., Kalliokoski R., Luotonen J., Timonen M., Mäkelä P.H. Ab response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr Infect Dis 1986, 5(1):39-44.
15. Lottenbach K.R., Mink C.M., Barenkamp S.J., Anderson E.L., Homan S.M., Powers D.C. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect Immun 1999, 67(9):4935-4938.
16. Mäkelä P.H., Leinonen M., Pukander J., Karma P. A study of the pneumococcal vaccine in prevention of clinically acute atttacks of recurrent Otitis media. Rev Infect Dis 1981, Suppl.:S124-S132.
17. Obaro S.K., Huo Z., Banya W.A., Henderson D.C., Monteil M.A., Leach A., et al. A glycoprotein pneumococcal conjugate vaccine primes for Ab responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr Infect Dis J 1997, 16(12):1135-1140.
18. O'Brien K.L., Steinhoff M.C., Edwards K., Keyserling H., Thoms M.L., Madore D. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. Pediatr Infect Dis J 1996, 15(5):425-430.
19. Pichichero M.E., Shelly M.A., Treanor J.J. Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers. Pediatr Infect Dis J 1997, 16(1):72-74.
20. Pomat W.S., Lehmann D., Sanders R.C., Lewis D.J., Wilson J., Rogers S., et al. Immunoglobulin G Ab responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea. Infect Immun 1994, 62(5):1848-1853.
21. Rose M.A., Schubert R., Kujumdshiev S., Kitz R., Zielen S. Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma. Int J Clin Pract 2006, 60(11):1425-1431.
22. Sell S.H., Wright P.F., Vaughn W.K., Thompson J., Schiffman G. Clinical studies of pneumococcal vaccines in infants I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Rev Infect Dis 1981, 3(Suppl.):S97-S107.
23. Silk H., Zora J., Goldstein J., Tinkelman D., Schiffman G. Response to pneumococcal immunization in children with and without recurrent infections. J Asthma 1998, 35(1):101-112.
24. Sloyer J.L., Ploussard J.H., Karr L.J., Schiffman G.D. Immunologic response to pneumococcal polysaccharide vaccine in infants. Ann Otol Rhinol Laryngol Suppl 1980, 89(3 Pt 2):351-356.
25. Sorensen R.U., Leiva L.E., Javier F.C., Sacerdote D.M., Bradford N., Butler B., et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol 1998, 102(2):215-221.
26. Tangsinmankong N., Kamchaisatian W., Day N.K., Sleasman J.W., Emmanuel P.J. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy. Ann Allergy Asthma Immunol 2004, 92(5):558-564.
27. Teele D.W., Klein J.O., Bratton L., Fisch G.R., Mathieu O.R., Porter P.J., et al. Use of pneumococcal vaccine for prevention of recurrent acute Otitis media in infants in Boston. The Greater Boston Collaborative Otitis Media Study Group. Rev Infect Dis 1981, 3 Suppl:S113-S118.
28. Temple K., Greenwood B., Inskip H., Hall A., Koskela M., Leinonen M. Ab response to pneumococcal capsular polysaccharide vaccine in African children. Pediatr Infect Dis J 1991, 10(5):386-390.
29. Weibel R.E., Vella P.P., McLean A.A., Woodhour A.F., Davidson W.L., Hilleman M.R. Studies in human subjects of polyvalent pneumococcal vaccines (39894). Proc Soc Exp Biol Med 1977, 156(1):144-150.
30. Witt C.S., Pomat W., Lehmann D., Alpers M.P. Antibodies to pneumococcal polysaccharides in pneumonia and response to pneumococcal vaccination in young children in Papua New Guinea. Clin Exp Immunol 1991, 83(2):219-224.
31. Cano F.R., Querry M.V., Tarrant C.J., Ritchey M.B., Schiffman G. Ab responses after immunization with polyvalent pneumococcal vaccine containing 10, 25, or 50 micrograms of 14 polysaccharide types per dose. Proc Soc Exp Biol Med 1983, 173(4):579-582.
32. Go E.S., Ballas Z.K. Anti-pneumococcal Ab response in normal subjects: a meta-analysis. J Allergy Clin Immunol 1996, 98(1):205-215.
33. Hilleman M.R., Carlson A.J., McLean A.A., Vella P.P., Weibel R.E., Woodhour A.F. Streptococcus pneumonia polysaccharide vaccine: age and dose responses, safety, persistence of Ab, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev Infect Dis 1981, 3:S31-S42.
34. Robbins J.B., Austrian R., Lee C.J., Rastogi S.C., Schiffman G., Henrichsen J., et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983, 148(December (6)):1136-1159.
35. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports April 04, 1997, 46(RR-08);1-24. [accessed July 13, 2011]. http://www.cdc.gov/mmwr/preview/mmwrhtml/00047135.htm.
36. World Health Organization. 23-valent pneumococcal polysaccharide vaccine WHO position paper. Wkly Epidemiol Rec 2008;83(42) 2008:373-84. [accessed July 13, 2011]. http://www.who.int/wer/2008/wer8342.pdf.
37. Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine, recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59(RR-11). [accessed July 13, 2011]. http://www.cdc.gov/mmwr/PDF/rr/rr5911.pdf.
38. Thompson S.G., Higgins J.P. How should meta-regression analyses be undertaken and interpreted?. Stat Med 2002, 21(11):1559-1573.
39. Sidik K., Jonkman J.N. A note on variance estimation in random effects meta-regression. J Biopharm Stat 2005, 15(5):823-838.
40. Rijkers G.T., Sanders E.A., Breukels M.A., Zegers B.J. Infant B cell responses to polysaccharide determinants. Vaccine 1998, 16(14-15):1396-1400.
41. Vos Q., Lees A., Wu Z.Q., Snapper C.M., Mond J.J. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 2000, 176:154-170.
42. Hozo S.P., Djulbegovic B., Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5(1):13.
43. Stata FAQ. How can I run a piecewise regression in Stata? UCLA: Academic Technology Services, Statistical Consulting Group from [accessed October 1, 2009]. http://www.ats.ucla.edu/stat/stata/faq/piecewise.htm.
44. Schiffman G., Douglas R.M., Bonner M.J., Robbins M., Austrian R. A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the Ab response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J Immunol Methods 1980, 33(2):133-144.
45. Wernette C.M., Frasch C.E., Madore D., Carlone G., Goldblatt D., Plikaytis B., et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003, 10(July (4)):514-519.
46. Siber G.R., Priehs C., Madore D.V. Standardization of Ab assays for measuring the response to pneumococcal infection and immunization. Pediatr Infect Dis J 1989, 8(1 Suppl.):S84-S91.
47. Concepcion N.F., Frasch C.E. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001, 8(March (2)):266-272.
48. Quataert S.A., Kirch C.S., Wiedl L.J., Phipps D.C., Strohmeyer S., Cimino C.O., et al. Assignment of weight-based Ab units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 1995, 2(5):590-597.
49. Siber G.R., Chang I., Baker S., Fernsten P., O'Brien K.L., Santosham M., et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007, 25(May (19)):3816-3826.
50. Henckaerts I., Goldblatt D., Ashton L., Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low Ab concentrations in pediatric sera. Clin Vaccine Immunol 2006, 13(3):356-360.
51. Leach A., Ceesay S.J., Banya W.A., Greenwood B.M. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr Infect Dis J 1996, 15(April (4)):333-339.
52. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000, 19(March (3)):187-195.
53. Roitt I.M., Brostoff J., Male D. Immunology 1985, CV Mosby Co. Ltd., Toronto, p. 7.9-8.4.
54. Howard J.G., Christie G.H., Courtenay B.M., Leuchars E., Davies A.J. Studies on immunological paralysis VI. Thymic-independence of tolerance and immunity to type 3 pneumococcal polysaccharide. Cell Immunol 1971, 2(6):614-626.
55. Cook I.F., Pond D., Hartel G. Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 2007, 25(25):4767-4774.
56. Austrian R. Vaccines of pneumococcal capsular poly-saccharides and the prevention of pneumococcal pneumonia. The role of immunological factors in infectious, allergic and auto-immune processes 1976, 79-89. Raven Press, New York. R.F. Beers, E. Basset (Eds.).
57. Yeh S.H., Gurtman A., Hurley D.C., Block S.L., Schwartz R.H., Patterson S., et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010, 126(September (3)):e493-e550.
58. Kieninger D.M., Kueper K., Steul K., Juergens C., Ahlers N., Baker S., et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010, 28(25):4192-4203.
59. Baxendale H.E., Johnson M., Stephens R.C., Yuste J., Klein N., Brown J.S., et al. Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease. Clin Exp Immunol 2008, 151(1):51-60.
60. Lucas A.H., Moulton K.D., Tang V.R., Reason D.C. Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F. Infect Immun 2001, 69(February (2)):853-864.
61. Kolibab K., Smithson S.L., Rabquer B., Khuder S., Westerink M.A. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoire. Infect Immun 2005, 73(November (11)):7465-7476.
62. O'Brien K. Pneumococcal regional serotype distribution for pneumococcal AMC TPP; 2008. [accessed April 12, 2011]. http://www.vaccineamc.org/files/TPP_Codebook.pdf.
63. Rodgers G.L., Arguedas A., Cohen R., Dagan R. Global serotype distribution among Streptococcus pneumoniae isolates causing Otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 2009, 27(29):3802-3810.
64. Timens W., Boes A., Rozeboom-Uiterwijk T., Poppema S. Immaturity of the human splenic marginal zone in infancy Possible contribution to the deficient infant immune response. Pediatr Res 2002, 52(2):245-250.
65. Zhang R., Wang Q.J., Xu J.M., Jiang L., Shou W.Z., Yin Y. Expression of CD21 in peripheral blood B lymphocytes of neonates. Zhongguo Dang Dai Er Ke Za Zhi 2007, 9(6):546-548. [abstract].
66. MacNair J.E., Desai T., Teyral J., Abeygunawardana C., Hennessey J.P. Alignment of absolute and relative molecular size specifications for a polyvalent pneumococcal polysaccharide vaccine (PNEUMOVAX 23). Biologicals 2005, 33(1):49-58.
67. Sørensen U.B., Henrichsen J., Chen H.C., Szu S.C. Covalent linkage between the capsular polysaccharide and the cell wall peptidoglycan of Streptococcus pneumoniae revealed by immunochemical methods. Microb Pathog 1990, 8(May (5)):325-334.
68. Schwandner R., Dziarski R., Wesche H., Rothe M., Kirschning C.J. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 1999, 274(25):17406-17409.
69. Moreau M, Recent developments in the characterisation of pneumococcal conjugate vaccines. In: Biological beyond 2000, challenges for quality standards in an evolving field. European Department for the Quality of Medicines, September 27-28, 1999, Strasbourg, France. Published in PHARMEUROPA Special Issue, BIO-2000.
70. Hostetter M.K. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J Infect Dis 1986, 153(4):682-693.
71. Fagarasan S., Honjo T. T-Independent immune response: new aspects of B cell biology. Science 2000, 290(5489):89-92.
72. Sun Y., Park M.K., Kim J., Diamond B., Solomon A., Nahm M.H. Repertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B. Infect Immun 1999, 67(3):1172-1179.
73. Snapper C.M., Shen Y., Khan A.Q., Colino J., Zelazowski P., Mond J.J., et al. Distinct types of T-cell help for the induction of a humoral immune response to Streptococcus pneumoniae. Trends Immunol 2001, 22(6):308-311.